


**Edwards Cardioband Tricuspid  
Valve Reconstruction System**

# The Right Solution for the Right Side



The first transcatheter device designed to treat  
patients with tricuspid regurgitation (TR)



# Severe tricuspid regurgitation is largely undertreated.

Patient mortality is significant.


<1% are treated surgically<sup>1\*</sup>

>36% one-year mortality rate for severe TR<sup>2</sup>

Did you know?

90% of severe TR cases is secondary or functional with annular reduction being the main cause.<sup>5</sup>


- Many patients diagnosed with symptomatic tricuspid regurgitation are medically managed
- Tricuspid regurgitation can have a negative impact on patient quality of life<sup>3,4</sup>



\* Based on US data.

# Cardioband Tricuspid Valve Reconstruction System.

The first-ever,  
CE Marked  
transcatheter  
tricuspid annular  
reduction system



Designed to safely and effectively  
reduce tricuspid regurgitation  
through annular reduction.<sup>6,7</sup>

- **Restores** valve to a more functional state, facilitating leaflet coaptation
- **Enables** annular reduction based on each patient's anatomy
- **Supports** real-time adjustment and confirmation of procedural results

## Did you know?


For surgical techniques, long term studies suggest that ring annuloplasty surgery repairs are more durable than suture annuloplasty repairs.<sup>8</sup>



# Cardioband Tricuspid System and its key advantages.

## Annular reconstruction benefits:

- Addresses annular dilatation, the main physiological cause of TR<sup>1</sup>
- Allows real-time intraprocedural adjustment and results confirmation<sup>7</sup>
- Facilitates leaflet coaptation<sup>6</sup>
- Preserves native anatomy with supra-annular fixation<sup>7</sup>
- Enables future possible treatment options<sup>7</sup>




Tricuspid valve with annular flattening and dilatation due to severe TR<sup>1</sup>

# Discover the 3 main steps in our animated procedure.<sup>7</sup>




## ➤ 1. Access

Insert Cardioband delivery system into the right atrium using a transfemoral approach.




## ➤ 2. Deploy

Deploy implant via a steerable catheter to navigate around the tricuspid annulus, securing the implant with stainless steel anchors.



## ➤ 3. Adjust

Introduce the size adjustment tool over a wire and rotate the adjustment knob clockwise for implant contraction to reduce annular diameter.




Edwards Cardioband  
Tricuspid Valve  
Reconstruction System<sup>7</sup>

## Did you know?


The Cardioband tricuspid system is purposefully designed for controlled and stabilized catheter movements.<sup>7</sup>

## Designed for a precise positioning in patient anatomy.

- Offers different implant sizes for each patient with a Cardioband implant working length from 76 to 116 mm.
- Treats the tricuspid valve annulus (Aorta to Coronary Sinus) from a range of 73 to 120 mm.



## Implant delivery system







Clinical results show the  
Cardioband Tricuspid System  
safely and effectively reduces  
tricuspid regurgitation and  
improves quality of life.<sup>6</sup>

## Edwards Cardioband Tricuspid Valve Reconstruction System

- **Reduce** the annulus based on each patient's anatomy<sup>7</sup>
- **Repair** with real-time confirmation of results<sup>7</sup>
- **Restores** valve to a more functional state<sup>6</sup>



Visit  
**Edwards.com/  
CardiobandTR**  
for more  
information



Contact us  
to join the  
Cardioband  
program

### References

1. Fender, E. A., et al 2018. Isolated tricuspid regurgitation: outcomes and therapeutic interventions. *Heart*. 104(10), 798–806.
2. Nath et al., 2004. Impact of tricuspid regurgitation on long-term survival. *J Am Coll Cardiol*. 43:405-409.
3. Antunes et al., 2017. Management of tricuspid valve regurgitation: Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease. *Eur J Cardiothorac Surg*. 52:1022–1030.
4. Del Forno et al., 2018. Recent advances in managing tricuspid regurgitation. *F1000Res*. 7: 355.
5. Mutlak et al., 2007. Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation. *Journal of the American Society of Echocardiography*. 20, 405–408.
6. Nickenig et al., 2021. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. *EuroIntervention*. 16:e1264-e1271. DOI: 10.4244/EIJ-D-20-01107
7. Edwards Cardioband Tricuspid Valve Reconstruction System Instructions For Use, 2021. DOC-0137600A.
8. Navia et al., 2010. Surgical management of secondary tricuspid valve regurgitation: Annulus, commissure, or leaflet procedure?. *J Thorac Cardiovasc Surg*. 139(6):1473-1482.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](http://eifu.edwards.com) where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, and Cardioband are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0189 v2.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](http://edwards.com)



Edwards